Lilly Expands Zepbound Access via LillyDirect: All approved single-dose vial strengths of Zepbound (tirzepatide), including 12.5 mg and 15 mg, are now available for $499 per month through ...

Through the Zepbound Self Pay Journey Program, designed to support patients throughout their obesity treatment journey, the 7.5 mg ($599), 10 mg ($699), 12.5 mg ($849), and 15 mg ($1,049) doses ...

1 Zepbound Self Pay Journey Program lowers the price of the 7.5 mg, 10 mg, 12.5 mg and 15 mg vials only on first fill and when prescriptions are refilled within 45 days of their previous delivery.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Through the Zepbound Self Pay Journey Program, designed to support patients throughout their obesity treatment journey, the 7.5 mg ($599), 10 mg ($699), 12.5 mg ($849), and 15 mg ($1,049) doses ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through ...